Toward new therapies for ocular inflammation.
While the use of this type of therapy and its application are far from immediate clinical application, the theory to support this approach is plausible. Most forms of anti-inflammatory therapy employed for ocular inflammatory diseases including iritis, scleritis, and chorioretinitis are derived from the success of these therapies for other organ systems. Just as ophthalmologists have the unique opportunity to visualize the hallmarks of the immune response, so do ophthalmologists have the unique opportunity to test this therapeutic approach which we speculate could offer improved efficacy and specificity over current modalities. Technological advances have helped to create an exciting era in ophthalmology. We believe that this technology can eventually be applied to the treatment of inflammatory diseases involving other body systems, as well as those primarily involving the eye.
Rosenbaum
J T
JT
Case Eye Institute, Oregon Health Sciences University, Portland, Oregon 97201, USA. rosenbaj@ohsu.edu
Becker
M D
MD
Smith
J R
JR
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000276:immunology; D006801:Humans; D015423:Scleritis / Q000188:drug therapy* / Q000276:immunology; D014605:Uveitis / Q000188:drug therapy* / Q000276:immunology
D000893:Anti-Inflammatory Agents; D015815:Cell Adhesion Molecules